Initial management of intermediate- and high-risk pulmonary embolism

Q: What is the clinical evidence from this study?

Study design: Review. Population: Intermediate- and high-risk pulmonary embolism. Intervention: Anticoagulation and advanced reperfusion therapies.

Q: What does this research mean for the field?

Immediate parenteral anticoagulation is essential for intermediate-high-risk and high-risk pulmonary embolism, with advanced reperfusion therapies indicated for high-risk patients and those with hemodynamic deterioration. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Asher A. Mendelson; Lana A. Castellucci; Sebastian Mafeld; Kerstin de Wit; for Pulmonary Embolism Canada

doi:10.1503/cmaj.250944

July 12, 2026Canadian Medical Association JournalOpen Access

Initial management of intermediate- and high-risk pulmonary embolism

View Full Paper

Ask AI

Bookmark

Share

Key result

Immediate anticoagulation anchors intermediate/high-risk PE care, reserving advanced reperfusion for high-risk or deteriorating cases.

Figures

Why the study?

Selection of patients with pulmonary embolism for advanced therapy is complex, with competing risks and benefits and a lack of high-level randomized evidence to guide decision-making.

Key Points

To review the acute evaluation, clinical risk stratification, and advanced therapeutic options for intermediate-high-risk and high-risk pulmonary embolism.
Narrative synthesis of recent clinical guidelines (2019 ESC and 2026 AHA) and clinical trials evaluating diagnosis and management of intermediate- and high-risk pulmonary embolism.
Assessment of risk stratification tools, including computed tomography, echocardiography, and cardiac biomarkers, to direct parenteral anticoagulation and advanced interventions.
Between 9% and 11% of patients diagnosed with pulmonary embolism die within 30 days, with PE-related death occurring in 2% and bleeding-related death occurring in 0.5%.
High-risk pulmonary embolism accounts for 5% to 10% of cases and carries an in-hospital mortality of 15% to 50% (rising to 65% to 90% during cardiac arrest), whereas intermediate-high-risk PE confers 5% to 15% short-term mortality.
Right ventricular dysfunction and elevated cardiac biomarkers identify heightened risk, with normotensive cardiogenic shock (cardiac output ≤ 2.2 L/min/m²) present in 34% of intermediate-risk patients despite normal blood pressure.

Structured PICO

P

Population

Patients with intermediate- and high-risk pulmonary embolism (PE).

I

Intervention

Initial management including immediate parenteral anticoagulation (preferably low-molecular-weight heparin) and advanced reperfusion therapies (systemic thrombolysis, catheter-based interventions, or extracorporeal membrane oxygenation) for select patients.

Risk stratification is essential in acute pulmonary embolism to guide the use of immediate anticoagulation and to identify patients who may benefit from advanced reperfusion therapies.

Limitations

Lack of high-level randomized evidence to guide decision-making for advanced therapies in intermediate-high-risk pulmonary embolism.
Equitable access to advanced pulmonary embolism therapies across geographic regions and within health care systems remains a challenge.

Implication

Risk stratification guides acute PE therapy selection now; extends guidelines but leaves optimal advanced intervention choice open.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mendelson et al. (2026) conducted a review in Intermediate- and high-risk pulmonary embolism. Anticoagulation and advanced reperfusion therapies was evaluated. Immediate parenteral anticoagulation is required for intermediate-high-risk and high-risk pulmonary embolism, with advanced reperfusion therapies indicated for high-risk patients and those who deteriorate.

synapsesocial.com/papers/6a5600ff10535b590d162452 https://doi.org/10.1503/cmaj.250944

View Full Paper

Ask AI

Bookmark

Share

Initial management of intermediate- and high-risk pulmonary embolism

Figures

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Initial management of intermediate- and high-risk pulmonary embolism

Figures

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading